In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IST: The Big Bang Theory of Device Innovation

Executive Summary

Assembling a Dream Team of surgeons, including those of The Texas Back Institute, as well as leading medical device companies, IST sought to create an incubator in spine unparalleled in its ability to bring new technology to market. The only thing is, the model didn't work. Now, IST has shifted gears and is pursuing a mega-roll up strategy.
Advertisement

Related Content

IST Finds a New Model and Some Investors
IST Finds a New Model and Some Investors
Orthopedic Seed Funding in the City
Orthopedic Seed Funding in the City
Texas Back Institute: Spine's Technology Laboratory
Texas Back Institute: Spine's Technology Laboratory
Medtronic Sofamor Danek: The Trials of the Front Runner
ATI: Is This the Model for Device Development?
Medtronic Sofamor Danek: The Trials of the Front Runner
ATI: Is This the Model for Device Development?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002545

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel